Gyre Therapeutics, Inc. GYRE Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gain/loss on asset sales?
- Gyre Therapeutics, Inc. (GYRE) reported gain/loss on asset sales of -$16K in Q1 2026.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.